Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy

NCT03381729 is registered in ClinicalTrials.gov with Novartis Gene Therapies as lead sponsor.

NCT NCT03381729
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03381729 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Lead sponsor
Novartis Gene Therapies
Phase
Phase 1
Overall status
Terminated
Start date
December 14, 2017
Completion date
November 18, 2021
Enrollment
32 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy